Haystack Project is a non-profit enabling rare and ultra-rare disease patient advocacy organizations to highlight and address systemic obstacles to patient access. Our core mission is to evolve health care payment and delivery systems to make innovative quality treatments accessible to the patients they were meant to reach.
As always, we have some interesting findings for you in today’s newsletter, including what former FDA executive JANET WOODCOCK is up to next…
…this news that former FDA Principal Deputy Commissioner JANET WOODCOCK, who retired earlier this year from the agency, has joined the Haystack Project as a “mission-focused advisor.” Woodcock told The Pink Sheet that she does not plan to interact directly with the FDA as part of the project, and also has no plans to work directly with or represent any specific companies.
Pink Sheet covers Haystack Project’s work
Read article here.
The Siegel Rare Neuroimmune Association (SRNA) is first to leverage Haystack Project’s Health Equity in Access to Treatments (“HEAT”) initiative. SRNA is working with Haystack Project to investigate health equity issues in neuroimmune disorders. Specifically, the project seeks to (a) understand variability in access, disease burden and lived experience of patient and caregivers, (b) proactively identify the barriers to diagnosis, specialists and treatments that shape a Black, Latinx, Asian or Native American’s journey, and (c) assess and address the representativeness of the SRNA’s outreach, education and members
Learn more here
Haystack successfully advocated for patients and experts to have an increased role
during the FDA review process for treatments for rare diseases!
Read more here.